4//SEC Filing
Molecular Insight Pharmaceuticals, Inc. 4
Accession 0001005477-07-000659
CIK 0001340752operating
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 3:03 PM ET
Size
17.7 KB
Accession
0001005477-07-000659
Insider Transaction Report
Form 4
FRANK DANIEL
Director
Transactions
- Conversion
Common Stock, par value $0.01 per share
2007-02-01+12,626→ 139,113 total - Conversion
Common Stock Purchase Warrant (right to buy)
2007-02-01$3.96/sh−12,626$49,999→ 0 totalFrom: 2004-03-04Exp: 2011-09-28→ Common Stock, par value $0.01 per share (12,262 underlying) - Conversion
Common Stock, par value $0.01 per share
2007-02-01+72,120→ 72,120 total - Conversion
Series C Convertible Preferred Stock
2007-02-01−1,488→ 0 totalFrom: 2005-03-29→ Common Stock, par value $0.01 per share (54,367 underlying) - Conversion
Common Stock, par value $0.01 per share
2007-02-01+54,367→ 126,487 total - Conversion
Series B Convertible Preferred Stock
2007-02-01−1,894→ 0 totalFrom: 2004-03-04→ Common Stock, par value $0.01 per share (72,120 underlying)
Footnotes (5)
- [F1]This Form 4 is being filed in connection with an initial public offering ("IPO") by Molecular Insight Pharmaceuticals, Inc. (the "Company"). Daniel Frank is a director of Molecular Insight Pharmaceuticals, Inc. (the "Company"). Mr. Frank owns (i) 139,113 shares of the common stock of the Company, par value $0.01 per share (the "Shares") and (ii) stock options to purchase 8,333 Shares (the "Options") which are currently exercisable or which are exercisable within 60 days of the date of this Form 4. Mr. Frank is a Managing Director of Cerberus Capital Management, L.P., an affiliate of which, Cerberus Partners, L.P., owns certain securities of the Company, all of which are subject to the sole voting and investment authority of Stephen Feinberg.
- [F2]Mr. Feinberg, in his capacity as the holder of sole voting and investment authority of more than 10.0% of the Shares pursuant to Reg. 13d-3, separately files statements pursuant to Sections 13 and 16 of the Securities Exchange Act of 1934, as amended. Mr. Frank does not exercise any voting, investment or other authority with respect to the Shares separately reported by Mr. Feinberg and he disclaims beneficial ownership thereof.
- [F3]Prior to consummation of the IPO, Mr. Frank owned 1,894 shares of the Series B Convertible Preferred Stock of the Company, par value $0.01 per share (the "Series B Preferred Stock"). The Series B Preferred Stock has no expiration date. In connection with the IPO, the Series B Preferred Stock automatically converted into 72,120 Shares, which number of Shares includes accrued and unpaid dividends on the Series B Preferred Stock.
- [F4]Prior to consummation of the IPO, Mr. Frank owned 1,488 shares of the Series C Convertible Preferred Stock of the Company, par value $0.01 per share (the "Series C Preferred Stock"). The Series C Preferred Stock has no expiration date. In connection with the IPO, the Series C Preferred Stock automatically converted into 54,367 Shares, which number of Shares includes accrued and unpaid dividends on the Series C Preferred Stock.
- [F5]Prior to consummation of the IPO, Mr. Frank owned a Common Stock Purchase Warrant (the "2004 Warrant") to acquire 12,626 Shares. In connection with the IPO, the 2004 Warrant was exercised for 12,626 Shares.
Documents
Issuer
Molecular Insight Pharmaceuticals, Inc.
CIK 0001340752
Entity typeoperating
IncorporatedMA
Related Parties
1- filerCIK 0001340752
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 3:03 PM ET
- Size
- 17.7 KB